DIABETES CARE
hamburger

PRESS RELEASES AND NOTIFICATIONS

DIABETES NEWS

ABBOTT AND BIGFOOT BIOMEDICAL ANNOUNCE COLLABORATION TO DEVELOP BREAKTHROUGH DIABETES TECHNOLOGIES

Published on: 07.13.2017
Abbott (NYSE: ABT) and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle® Libre glucose sensing technologywith Bigfoot's insulin delivery solutions in the United States.

ABBOTT SECURES HEALTH CANADA LICENSE FOR FREESTYLE® LIBRE SYSTEM FOR PEOPLE WITH DIABETES

Published on: 06.29.2017
Abbott (NYSE: ABT) today announced the Health Canada license of its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for Canadian adults with diabetes.

ABBOTT ANNOUNCES NATIONAL REIMBURSEMENT FOR FREESTYLE® LIBRE IN FRANCE, PROVIDING ACCESS TO REVOLUTIONARY TECHNOLOGY FOR PEOPLE WITH DIABETES

Published on: 05.08.2017
Abbott today announced that the French Health Ministry has granted national reimbursement across France for FreeStyle® Libre—Abbott's revolutionary glucose monitoring technology that removes the need for routine finger sticks1 for people with diabetes.

REAL-WORLD DATA FROM ABBOTT'S FREESTYLE® LIBRE SHOW ASSOCIATION BETWEEN HIGHER FREQUENCY OF GLUCOSE MONITORING AND IMPROVED GLUCOSE CONTROL FOR PEOPLE WITH DIABETES

Published on: 02.15. 2017
Abbott (NYSE: ABT) today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle® Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels.

ABBOTT RECEIVES FDA APPROVAL FOR THE FREESTYLE LIBRE PROTM SYSTEM, A REVOLUTIONARY DIABETES SENSING TECHNOLOGY FOR HEALTHCARE PROFESSIONALS TO USE WITH THEIR PATIENTS

Published on: 09.28. 2016
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring (CGM) system for healthcare professionals to use with their patients with diabetes.


ABBOTT RECEIVES APPROVAL IN AUSTRALIA FOR FREESTYLE LIBRE - THE REVOLUTIONARY GLUCOSE MONITORING SYSTEM FOR PEOPLE WITH DIABETES

Published on: 02.16.2016
Today, Abbott (NYSE:ABT) announced that it has received approval from the Therapeutic Goods Administration (TGA) in Australia for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology.


CHILDREN IN EUROPE NOW HAVE ACCESS TO FIRST-OF-ITS-KIND DIABETES SENSING TECHNOLOGY – ELIMINATES ROUTINE FINGER PRICKS

Published on: 02.04. 2016
Today, Abbott (NYSE: ABT) announced that it has obtained CE Mark (Conformité Européenne) for the FreeStyle Libre flash glucose monitoring system indicated for children and teens with diabetes aged 4-17 years old.


NEW BLOOD GLUCOSE METER PROVIDES PEOPLE WITH DIABETES AN ACCURATE, AFFORDABLE SOLUTION FOR GLUCOSE TESTING - WITHOUT INSURANCE COPAYS

Published on: 04.15. 2015
The cost of insurance premiums and employee medical claims continues to rise in the United States, which is especially challenging for people living with chronic conditions such as diabetes.

ABBOTT NEWS


CLICK HERE


ADC-01541 Ver 4.0 06/17
 

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

DO YOU WISH TO LEAVE THIS SITE?

true
accessibility

NO

YESNO
accessibility

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

DO YOU WISH TO LEAVE THIS SITE?

YESNO